Brief: Karolinska Development Portfolio Co Publishes Data On Golexanolone
Sept 4 (Reuters) - Karolinska Development AB KDEV.ST: KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY UMECRINE COGNITION PUBLISHES DATA SHOWING SUSTAINED EFFECT OF GOLEXANOLONE IN A PARKINSON'S DISEASE MODEL Source text: ID:nGNE4Z0pBl Further company coverage: KDEV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue